On Tuesday, Following Stocks were among the “Top Gainers” of U.S. Stock Market: Rosetta Resources, (NASDAQ:ROSE), Esperion Therapeutics, (NASDAQ:ESPR), Qihoo 360 Technology, (NYSE:QIHU), Express Scripts Holding, (NASDAQ:ESRX)
Rosetta Resources, (NASDAQ:ROSE), with shares gained 1.98%, closed at $17.02.
Esperion Therapeutics, (NASDAQ:ESPR), with shares jumped 0.61%, settled at $92.60.
Qihoo 360 Technology, (NYSE:QIHU), with shares climbed 2.20%, and closed at $51.20.
Scripts Holding, (NASDAQ:ESRX), surged 1.60%, and closed at $86.77.
Latest NEWS regarding these Stocks are depicted underneath:
Rosetta Resources, Inc. (NASDAQ:ROSE)
Formerly on March 10, Rosetta Resources, Inc. (ROSE), declared that it has priced an underwritten public offering of 12,000,000 shares of the Corporation’s ordinary stock. The Corporation has granted the underwriter a 30-day option to purchase up to an additional 1,800,000 shares of ordinary stock. The Corporation anticipates to receive total gross proceeds (before underwriting discounts and estimated offering expenses) of about $206.4 million, or about $237.4 million if the underwriter exercises its option to purchase additional shares of ordinary stock in full.
Rosetta Resources Inc., an independent exploration and production corporation, attains and develops onshore energy resources in the United States. It owns producing and non-producing oil, natural gas liquids (NGLs), and natural gas properties in proven or prospective basins that are primarily located in the Eagle Ford shale in South Texas and in the Permian Basin in West Texas.
Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Formerly on March 24, Esperion Therapeutics, Inc. (ESPR), declared the closing of its follow-on public offering of 2,012,500 shares of ordinary stock, offered at a price to the public of $100.00 per share, which comprises the exercise in full by the underwriters of their option to purchase 262,500 additional shares of ordinary stock. This exercise brings the net proceeds in the offering to $189.9 million, after deducting underwriting discounts and commissions and estimated expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, in addition to its other existing capital resources, to complete the clinical development of ETC-1002, counting development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.
Esperion Therapeutics, Inc., a biopharmaceutical corporation, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.
Qihoo 360 Technology Co. Ltd. (NYSE:QIHU)
Education Group (XUE), a leading national provider of personalized tutoring services for primary and secondary school students in China, declared updates pertaining to its Joint-Venture Contract with Qihoo 360 Technology Co. Ltd. (QIHU).
The Contract formed a joint-venture corporation, Sunshine Rabbit (Beijing) Technology Co., Ltd., in Beijing, on February 26, 2015, with registered capital of less than $5 million for the principal business purpose of pursuing online education opportunities. Xueda’s CEO and co-founder, Mr. Xin Jin, serves as Chairman of the Board for the joint venture. Mr. Junyi Li, a senior executive at Xueda, serves as CEO of the joint venture. Qihoo 360’s co-founder and president, Mr. Xiangdong Qi, and senior vice president, Mr. Guangdong Yu, serve, together with others, as Directors of the joint venture.
Qihoo 360 Technology Co. Ltd. provides Internet and mobile security products and services in the People’s Republic of China. Its core Internet security products comprise 360 Safe Guard, a solution for Internet security and system optimization; 360 Anti-Virus, an anti-virus application that uses multiple scan engines to protect users computers against various kinds of malware, in addition to 360 Mobile Safe, a security program for the Google Android, Apple iOS, and Windows smartphone operating systems.
Express Scripts Holding Company (NASDAQ:ESRX)
Formerly on March 10, New hepatitis C therapies with high price tags and the exploitation of loopholes for compounded medications drove a 13.1 percent raise in U.S. drug spending in 2014 – a rate not seen in more than a decade – according to new data released in the 2014 Express Scripts Holding Company (ESRX), Drug Trend Report.
Hepatitis C and compounded medications are responsible for more than half of the raise in overall spending. Not including those two therapy classes, 2014 drug trend (the year-over-year raise in per capita drug spending) was 6.4 percent.
Express Scripts Holding Corporation operates as a pharmacy benefit administration (PBM) corporation in the United States and Canada. The corporation operates through two segments, PBM and Other Business Operations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
